F. Morschhauser

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

John Raemaekers, Marc André, Massimo Federico et al. · Journal of Clinical Oncology · 2014 · 381 citations · Full text

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

Bruno Chetaille, François Bertucci, Pascal Finetti et al. · Blood · 2008 · 250 citations

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · Annals of Oncology · 2021 · 240 citations · Full text

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma

Sandra J. Strauss, F. Morschhauser, Jürgen Rech et al. · Journal of Clinical Oncology · 2006 · 148 citations · Full text

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

Harmony Leroy, Stéphane de Botton, Nathalie Grardel et al. · Leukemia · 2005 · 124 citations

Prognostic Evaluation, Real-time Quantitative Pcr, Prognostic Value +3